<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1378">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04344951</url>
  </required_header>
  <id_info>
    <org_study_id>UNIKINON-01/HOPE</org_study_id>
    <nct_id>NCT04344951</nct_id>
  </id_info>
  <brief_title>Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial</brief_title>
  <acronym>HOPE</acronym>
  <official_title>Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Athens General Hospital Hippokrateio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Athens General Hospital of Thoracic Diseases SOTIRIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Athens Sismanoglio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Divine Providence Hospital Pammakaristos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University General Hospital of Ioannina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Corfu General Hospital Agia Irini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label clinical study to evaluate the activity of chloroquine phosphate in
      patients with SARS-CoV-2 virus infection. The study aims to document possible prevention of
      pneumonia in patients staying at home and in improving the symptoms of SARS-CoV-2 pneumonia
      in patients who will be hospitalised.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Humanity has been experiencing a new pandemic of the SARS Coronavirus-19 virus (SARS-CoV-2)
      since December 2019, causing the disease known as COVID-19. As of March 23, 2020, there have
      been 382,341 documented episodes of infection worldwide, of which 16,567 have died. An
      important limitation in the treatment of the disease is the absence of drugs with known
      antiviral activity against SARS-CoV-2. Recent data suggest that chloroquine has sufficient in
      vitro activity against the SARS-CoV-2 virus by inhibiting virus entry into cells. It has
      recently been described that hydroxychloroquine significantly reduces the percentage of
      patients who have positive sputum in the SARS-CoV-2 virus within 6 days. However, the
      clinical efficacy of the drug has not been described and it has significant side effects,
      including more than 10% anorexia, headache, blurred vision, diarrhea or vomiting, and
      myocardiotoxicity. The frequency of adverse effects of chloroquine in combination with the
      well-known in vitro activity of chloroquine have led to the design of clinical trials around
      the world to document the benefits of its use. The present study will evaluate the activity
      of chloroquine phosphate in patients with SARS-CoV-2 virus infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, open label, Phase II study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>50% reduction in symptom score for patients with lower respiratory tract infection</measure>
    <time_frame>Day 8 visit from study initiation</time_frame>
    <description>Achieving 50% reduction in symptom score for patients with lower respiratory tract infection on day 8 visit from study initiation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lack of progression for patients with upper respiratory tract infection</measure>
    <time_frame>Day 8 visit from study initiation</time_frame>
    <description>Lack of progression to lower respiratory tract infection in patients enrolled in the study due to upper respiratory tract infection on day 8 visit from study initiation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the primary endpoint with respective patients not receiving the treatment</measure>
    <time_frame>Day 14 visit from study initiation</time_frame>
    <description>Lower respiratory tract infection rating takes place. The symptoms checked are: Cough, Chest pain, Dyspnea, expectoration. For each symptom score is given from 0 to 3 depending on the intensity and they are summed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment.</measure>
    <time_frame>Day 14 visit from study initiation</time_frame>
    <description>It is defined as the presence of both of the following:
Respiratory quotient (pO2 / FiO2) less than 150
Need for treatment with CPAP or mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs and SAEs</measure>
    <time_frame>Day 14 visit from study initiation</time_frame>
    <description>Frequency of AEs and SAEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pneumonia, Viral</condition>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>UNIKINON (Chloroquine phosphate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once a patient is considered eligible for the study, they will receive oral chloroquine phosphate. The total duration of treatment will be 7 days. The dosage will be 500mg every 12 hours. It is clarified that any other treatment at the discretion of the therapist is permitted except for the administration of hydroxychloroquine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UNIKINON (Chloroquine phosphate) 200mg tablets</intervention_name>
    <description>Two and a half tablets (500mg) twice daily for seven days.</description>
    <arm_group_label>UNIKINON (Chloroquine phosphate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Both genders

          -  For women of childbearing age, they should use or be willing to use a double
             contraceptive method during the study. A urine pregnancy test to exclude pregnancy
             will be performed prior to study initiation.

          -  Written consent after information provided by the patient or the legal representative
             in the event that the patient cannot consent.

          -  Upper respiratory or lower respiratory tract infection, as in Annexes II and III
             respectively.

          -  Positive respiratory secretion test for SARS-CoV-2 virus by molecular techniques or
             positive blood IgM titers.

        Exclusion Criteria:

          -  Under 18 years of age

          -  Denial of written consent

          -  Any patient case where it has been decided not to rejuvenate

          -  Serum AST values greater than 5 times the upper normal range

          -  QTc interval in rest electrocardiogram greater than 500msecs

          -  Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Sambatakou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Athens General Hospital &quot;Hippokrateio&quot;, 2nd department of Pathology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolaos Koulouris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Athens General Hospital of Thoracic Diseases &quot;SOTIRIA&quot;, 1st University Pulmonary Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Garyfallia Poulakou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Athens General Hospital of Thoracic Diseases &quot;SOTIRIA&quot;, 3rd University Pathology Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malvina Lada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Athens &quot;Sismanoglio&quot;, 2nd Department of Pathology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ioannis Baraboutis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Divine Providence Hospital &quot;Pammakaristos&quot;, Pathology Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Symeon Metallidis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University General Hospital of Thessaloniki AHEPA, 1st University Pathology Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haralambos Milionis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University General Hospital of Ioannina, 1st University Pathology Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilias Papanikolaou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corfu General Hospital Agia Irini, Pulmonary Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divine Providence Hospital &quot;Pammakaristos&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11144</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Baraboutis, MD</last_name>
      <phone>30 213 2042100</phone>
      <email>ioannisbaraboutis@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athens General Hospital &quot;Hippokrateio&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Sambatakou, MD</last_name>
      <phone>30 213 2088000</phone>
      <email>helensambatakou@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athens General Hospital of Thoracic Diseases &quot;SOTIRIA&quot;, 1st University Pulmonary Clinic</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Koulouris, MD</last_name>
      <phone>30 210 7763702</phone>
      <email>koulnik@med.uoa.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athens General Hospital of Thoracic Diseases &quot;SOTIRIA&quot;, 3rd University Pathology Clinic</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garyfallia Poulakou, MD</last_name>
      <phone>30 210 7763702</phone>
      <email>gpoulakou@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corfu General Hospital Agia Irini</name>
      <address>
        <city>Corfu</city>
        <zip>491 00</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilias Papanikolaou, MD</last_name>
      <phone>30 26610 33088</phone>
      <email>icpapanikolaou@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ilias Papanikolaou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina</name>
      <address>
        <city>Ioánnina</city>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haralambos Milionis, MD</last_name>
      <phone>30 26510 99736</phone>
      <email>hmilioni@uoi.gr</email>
    </contact>
    <investigator>
      <last_name>Haralambos Milionis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Sismanoglio&quot;</name>
      <address>
        <city>Maroúsi</city>
        <zip>151 26</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malvina Lada, MD</last_name>
      <phone>30 213 2058 001</phone>
      <email>malvinalada@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki AHEPA</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Symeon Metallidis, MD</last_name>
      <phone>30 2310 994656</phone>
      <email>metallidissimeon@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Symeon Metallidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <results_reference>
    <citation>Arabi YM, Murthy S, Webb S. COVID-19: a novel coronavirus and a novel challenge for critical care. Intensive Care Med. 2020 May;46(5):833-836. doi: 10.1007/s00134-020-05955-1. Epub 2020 Mar 3. Erratum in: Intensive Care Med. 2020 Mar 18;:.</citation>
    <PMID>32125458</PMID>
  </results_reference>
  <results_reference>
    <citation>Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.</citation>
    <PMID>32171740</PMID>
  </results_reference>
  <results_reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.</citation>
    <PMID>32205204</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Chloroquine phosphate</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

